http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2607935-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fadc18369dac6778fe6217aed49ada7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6432 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-482 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4826 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4853 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
| filingDate | 2010-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22c89a3b75dc9ea6e436118a320d1b13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e652cb1cf998325aa0d2c5b27a137378 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abf6c738d0ea1b72717dbace5593c3be |
| publicationDate | 2017-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2607935-T3 |
| titleOfInvention | Antidotes for factor Xa inhibitors and procedures for their use |
| abstract | An isolated polypeptide comprising (A) (i) the amino acid sequence of SEQ ID NO. 12 or 13 further comprising a modification in the autolysis loop of the heavy chain of SEQ ID NO. 12 or 13 or (ii) an amino acid sequence that has at least 95% sequence identity with SEQ ID NO. 12 or 13, and further comprising one or more mutations selected from the group consisting of Arg366Q / A, Lys370Q / A, Arg372Q / A, Arg376Q / A, and combinations thereof; wherein the autolysis loop corresponds to amino acid residues 366-376 of SEQ ID NO. one; (B) the amino acid sequence of SEQ ID NO. 20 or an amino acid sequence that has at least 95% sequence identity with SEQ ID NO. 20, in which the polypeptide does not contain the C-terminal end of wild-type factor Xa after the remaining amino acid corresponding to Arg429 of SEQ ID NO. 3; (C) the amino acid sequence of SEQ ID NO. 21 or an amino acid sequence that has at least 95% sequence identity with SEQ ID NO. 21, in which the polypeptide has Gln in the amino acid residue corresponding to Arg429 of SEQ ID NO. 3; or (D) the amino acid sequence of SEQ ID NO. 22 or an amino acid sequence that has at least 95% sequence identity with SEQ ID NO. 22, in which the polypeptide has Gln in the amino acid residue corresponding to Arg429 of SEQ ID NO. 3, and has Ala in the amino acid residue corresponding to Thr443 of SEQ ID NO. 3, in which the polypeptide (a) has a reduced procoagulant activity compared to wild-type factor Xa, (b) is capable of binding to a factor Xa inhibitor, and (c) is not assembled into a complex of prothrombinase |
| priorityDate | 2009-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 611.